COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study - 29/04/21
Doi : 10.1016/j.jbspin.2021.105131
Paolo Francesconi a, Fabrizio Cantini b, Francesco Profili a, Alessandro Mannoni c, Benedetta Bellini a, Maurizio Benucci d, ⁎ 
a Regional health agency of Tuscany epidemiology observatory, Florence, Italy
b Department of rheumatology, Azienda USL Toscana centro, Hospital of Prato, Prato, Italy
c Rheumatology unit, Hospital P. Palagi, Azienda USL – Toscana centro, Florence, Italy
d Rheumatology unit, S. Giovanni di Dio Hospital, Azienda USL – Toscana Centro, Via Torregalli 3, 50143 Florence, Italy
⁎Corresponding author.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Highlights |
• | The different screening methodology to capture cases of SARS-CoV-2 infections in patients with rheumatic diseases may result in a variation in the incidence of COVID-19 compared to the general population. |
• | Study confirms the role of corticosteroids in increasing the risk of SARS-CoV-2 infection in patients with chronic rheumatic diseases (RA, AS, PsA) rather than in while connective tissue diseases. |
• | Patients with chronic rheumatic diseases require careful surveillance through serological tests and confirmations with RT-PCR. |
Keywords : COVID-19, Rheumatic disease, B-DMARDs
Esquema
© 2021
Société française de rhumatologie. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 88 - N° 3
Artículo 105131- mai 2021 Regresar al número
Artículo precedente
- Camurati-Engelmann disease or Ribbing disease
- Jean-Jacques Dubost, Martin Soubrier
- May polyenthesitis follow COVID-19?
- Jacopo Ciaffi, Luana Mancarella, Elena Borlandelli, Giancarlo Facchini, Riccardo Meliconi, Francesco Ursini
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.